What is our microbiome discovery platform?
After a decade of research on the intestinal microbiota, Da Volterra has accumulated a unique knowledge and extensive library of samples collected in all our animal and human studies when exposed or not to antibiotic treatments or other drugs. We have built a proprietary discovery platform to collect and analyze microbiota samples and study the rich interactions between the commensal bacteria of the gut with their hosts.
By combining the best techniques of analysis and deep scientific review of both metagenomic and metabolomic changes in the intestinal microbiota, we are deciphering the mechanisms by which the intestinal microbiota influences host immunity, resistance to colonization of the gut by pathogenic bacteria, emergence of antibiotic resistance, as well as diseases such as obesity and depression.
At Da Volterra, we are fully convinced that the intestinal microbiota plays an important role in health maintenance, and we are committed to harness the full potential of the highly diverse intestinal microbiota.
Our team closely integrates physicians, biologists and computer scientists who collaborate to develop the data mining and machine learning techniques required to explore in depth the microbiota and translate our research into actionable products for drug development.
|Product|| ||Discovery||Preclinical||Phase 1||Phase 2||Phase 3||Market
|Microbiome Discovery Platform||Discovering metagenomic and metabolomic targets in the intestinal microbiota to support the development of novel therapeutic strategies|| || || || || ||